Isotopia Molecular Imaging, a company formed by a collaboration between The Metrontario Group and some of Israel's leading scientists in the field of radiopharmaceuticals, has started a partnership with Y-mAbs Therapeutics Inc, a late-stage clinical biopharmaceutical company, it was reported on Thursday.
The collaboration is aimed at the supply of the medical radioisotope no-carrier-added Lutetium-177 to support clinical development for 177Lu-DTPA-omburtamab intended for the treatment of B7-H3 positive Central Nervous System and Leptomeningeal Metastasis from tumours in adult patients.
Isotopia's Business Development manager, Keren Moshkoviz said, 'Isotopia, Like Y-mAbs aims to improve quality of life of cancer patients with Targeted Radionuclide Therapies. We are very pleased to establish this alliance making significant contribution to innovative and promising therapies for cancer patients worldwide. Isotopia is focusing on supporting clinical studies also for the next generation of radio isotope Tb161 that will be launched soon. We are confident that our growing development platform will make a big contribution to targeted therapies worldwide.'
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference